Hungary's largest drugmaker Gedeon Richter (RICHT: HB) says that the European Medicines Agency has accepted Richter's regulatory submission for the proposed biosimilar to teriparatide.
Teriparatide is the active ingredient US pharma major Eli Lilly’s osteoporosis treatment Forteo, which generated sales of $348.9 million in the third quarter of 2015.
The biosimilar teriparatide has been developed by its Richter-Helm BioTec GmbH subsidiary. According to the relevant license agreements, biosimilar teriparatide is expected to be launched under both Richter and STADA (Germany’s Stada Arzneimittel [SAZ: Xetra] labels in geographical Europe following the patent expiry of the original product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze